Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Doxil in Refractory Malignancies and Metastatic Breast Cancer
NCT00237627Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2001
- Primary completion
- Dec 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in breast cancer, ovarian cancer, leukemia and 4 more, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 year and Objective Response Rate. Started May 2001; status: completed.
02
Drugs
bortezomib
03
Conditions
breast cancerovarian cancerleukemialymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT00237627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237627.